PPARG and liposarcoma: As surgeryremains the mainstay of treatment for liposarcomas, with limited therapeuticoptions for unresectable, advanced disease, and investigation of PPARγ ligands for adjuvant therapy of liposarcomasor control of microscopic or minimal residual disease may still bewarranted.